➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
Boehringer Ingelheim
Mallinckrodt
McKinsey

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,039,451


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,039,451 protect, and when does it expire?

Patent 8,039,451 protects EUCRISA and is included in one NDA.

Protection for EUCRISA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-eight patent family members in twenty-four countries.

Summary for Patent: 8,039,451
Title:Boron-containing small molecules
Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Inventor(s): Baker; Stephen J. (Mountain View, CA), Akama; Tsutomu (Sunnyvale, CA), Bellinger-Kawahara; Carolyn (Redwood City, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Leyden; James J. (Malvern, PA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA)
Assignee: Anacor Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:12/507,010
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;

Drugs Protected by US Patent 8,039,451

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,039,451

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006214247 ⤷  Try it Free
Australia 2006333527 ⤷  Try it Free
Australia 2010203096 ⤷  Try it Free
Australia 2011200994 ⤷  Try it Free
Brazil PI0608431 ⤷  Try it Free
Brazil PI0621279 ⤷  Try it Free
Canada 2597982 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Colorcon
AstraZeneca
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.